Make an Inquiry
Accelerating Osteoarthritis Drug Development

Osteoarthritis presents a significant and complex therapeutic challenge, marked by progressive joint degeneration and limited treatment options. Protheragen stands as a specialized partner in the preclinical development of novel therapeutics for Osteoarthritis, leveraging deep scientific expertise and a focused commitment to advancing disease-modifying solutions. Protheragen offers comprehensive preclinical services encompassing target validation, lead optimization, pharmacology, and IND-enabling studies, ensuring a seamless transition from discovery to clinical readiness. The company’s integrated approach combines state-of-the-art platforms, robust in vivo and in vitro models, and rigorous data analytics to generate actionable insights and de-risk early-stage development. with a proven track record in regulatory compliance and a dedicated team of Osteoarthritis specialists, Protheragen delivers tailored strategies that align with the latest scientific advancements and regulatory expectations. Protheragen is committed to accelerating the development of effective Osteoarthritis therapeutics, empowering partners to achieve meaningful breakthroughs that address unmet clinical needs.

What is OsteoarthritisTargets for OsteoarthritisDrug Discovery and Development ServicesWhy Choose Us

What is Osteoarthritis

Osteoarthritis (OA) is a chronic, progressive joint disorder characterized by the degeneration of articular cartilage, remodeling of subchondral bone, and synovial inflammation. Its etiology is multifactorial, involving mechanical stress, genetic predisposition, aging, and biochemical changes. Chondrocyte dysfunction, increased matrix metalloproteinase activity, and elevated pro-inflammatory cytokines disrupt the balance between cartilage synthesis and degradation, leading to cartilage breakdown and joint tissue damage. OA primarily affects weight-bearing joints such as the knees, hips, and spine, but can also involve the hands and other joints. Risk factors include advanced age, female sex, obesity, previous joint injury, repetitive use, and metabolic disorders. Clinically, OA presents with joint pain, stiffness—often worse after periods of inactivity—and reduced mobility, which can ultimately impair quality of life. Physical examination may reveal joint tenderness, crepitus, bony enlargement, and decreased range of motion. Diagnosis is primarily clinical, supported by radiographic findings such as joint space narrowing and osteophyte formation. Laboratory tests are typically used to exclude other conditions. Treatment focuses on symptom management and functional improvement, including non-pharmacological measures (weight loss, exercise, physical therapy), pharmacological therapies (NSAIDs, intra-articular agents like diclofenac etalhyaluronate, hyaluronate-triamcinolone, or cell-mediated therapies such as TissueGene-C), and, in advanced cases, surgical intervention. Therapy is tailored to patient needs and comorbidities.

Launched Drugs

Structure Generic Name CAS Registry Number Molecular Formula Molecular Weight
diclofenac etalhyaluronate (USAN) 1608089-20-8
tissueGene-C; tonogenchoncel-L (USAN)
hyaluronate sodium/triamcinolone hexacetonide
img-51543-39-6-s--flurbiprofenesflurbiprofen-rec-inn-ban (S)-(+)-flurbiprofen; esflurbiprofen (Rec INN; BAN) 51543-39-6 C15 H13 F O2 244.261
img-301692-76-2-polmacoxib-prop-inn-usan polmacoxib (Prop INN; USAN) 301692-76-2 C18 H16 F N O4 S 361.387
chung-pa-juhn; chungpa-juhn; shinbaro
ibuprofen/famotidine
img-25775-90-0-z-capsaicincivamidezucapsaicin-rec-inn-usan (Z)-capsaicin; civamide; zucapsaicin (Rec INN; USAN) 25775-90-0 C18 H27 N O3 305.412
ketoprofen/omeprazole

Learn More

Targets for Osteoarthritis

Targets in Clinical or Later Phases of Development

Target Name Gene Symbol
acid sensing ion channel subunit 1 ASIC1
Acid-Sensing Ion Channel (ASIC) (nonspecified subtype)
aryl hydrocarbon receptor AHR
aldo-keto reductase family 1 member C2 AKR1C2
Gastric H+/K+-ATPase
Cyclooxygenase (COX) (nonspecified subtype)
caspase 1 CASP1
Carbonic Anhydrase (nonspecified subtype)
melanocortin 3 receptor MC3R
Matrix Metalloproteinase (MMP) (nonspecified subtype)

Osteoarthritis (OA) involves a complex interplay of molecular targets that drive joint degeneration, inflammation, and pain. Key targets include inflammatory mediators such as caspase 1 (CASP1) and the NLRP3 inflammasome, which promote the maturation and release of pro-inflammatory cytokines like IL-1β, amplifying cartilage breakdown. Nuclear factor kappa B (NF-κB) serves as a central transcriptional regulator, upregulating genes involved in inflammation and matrix degradation. Matrix metalloproteinases (MMPs) and cyclooxygenases (COX-1/PTGS1 and COX-2/PTGS2) are pivotal in cartilage matrix degradation, breaking down collagen and proteoglycans and producing prostaglandins that further exacerbate inflammation and pain. Ion channels such as acid-sensing ion channels (ASICs) and TRPV1 mediate pain transduction, while regulatory pathways involving the aryl hydrocarbon receptor (AHR) and glucocorticoid receptor (NR3C1) modulate cellular stress and inflammatory responses. Therapeutically, these targets offer diverse opportunities for intervention. Inhibitors of CASP1, NLRP3, and NF-κB are under investigation for their disease-modifying potential, aiming to curb inflammation and slow joint destruction. MMP inhibitors and selective COX-2 inhibitors (coxibs) have been explored, with coxibs widely used for symptom relief despite limited impact on disease progression. Agents targeting pain pathways, such as ASIC and TRPV1 antagonists, show promise in preclinical studies for alleviating OA pain. Modulation of regulatory receptors like AHR and NR3C1 presents additional avenues for controlling inflammation and tissue homeostasis. Ongoing research is focused on improving target specificity and minimizing side effects to develop effective, disease-modifying osteoarthritis therapies.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our In Vitro Efficacy Testing Service accelerates osteoarthritis drug discovery by providing comprehensive screening and characterization of therapeutic candidates. We evaluate key inflammatory mediators, catabolic enzymes, and signaling pathways using advanced biochemical, cellular, and functional assays, including ELISA, chemiluminescence, gene reporter, and patch-clamp techniques. Our platforms target Caspase 1, NF-κB, COX-1, COX-2, KCNQ2, TRPV1, and transthyretin. We deliver critical pharmacological parameters such as IC-50, EC-50, MIC, and MEC, enabling data-driven optimization of drug potency, efficacy, and safety for osteoarthritis treatments, thus supporting efficient and informed preclinical decision-making.

Caspase 1 Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells
Potassium Voltage-Gated Channel Subfamily Q Member 2 Prostaglandin-Endoperoxide Synthase 1
Prostaglandin-Endoperoxide Synthase 2 Transient Receptor Potential Cation Channel Subfamily V Member 1
Transthyretin

Learn More

Why Choose Us

Choosing Protheragen means partnering with a company that brings specialized expertise to every stage of Osteoarthritis research and drug development. Our professional teams are composed of experienced scientists and industry experts who are dedicated to advancing innovative therapeutics for Osteoarthritis. At Protheragen, we utilize advanced technology platforms that enable us to deliver high-quality, efficient, and reliable preclinical drug development services. Our proven track record in the field demonstrates our ability to consistently achieve results that meet the highest scientific and regulatory standards. We adhere strictly to international quality standards and maintain rigorous regulatory compliance throughout all phases of development, ensuring that every project is managed with the utmost integrity and precision. Protheragen is deeply committed to making a meaningful impact in Osteoarthritis therapeutics, striving to accelerate the discovery and development of effective new treatments. When you choose Protheragen, you can trust in our professionalism, reliability, and unwavering dedication to improving patient outcomes in Osteoarthritis.

FAQs for Our Services

Q: What are the main preclinical research challenges specific to Osteoarthritis drug development?

A: Osteoarthritis (OA) presents unique preclinical challenges, primarily due to the complexity and heterogeneity of the disease. Accurately modeling the progressive, multifactorial nature of OA in animals is difficult, as no single model fully recapitulates human disease pathology. Additionally, the slow progression of OA and variability in clinical presentation require careful selection and validation of in vivo and in vitro models. Our company addresses these challenges by offering a portfolio of validated OA models—including surgical, chemical, and spontaneous models—and by employing advanced imaging and histological techniques to ensure translational relevance.

Q: What are the key regulatory considerations for Osteoarthritis drug development in the preclinical stage?

A: Regulatory agencies such as the FDA and EMA require robust preclinical data demonstrating the safety, efficacy, and mechanism of action of new OA drug candidates. Specific considerations include the selection of relevant animal models, the use of validated endpoints (such as pain reduction, cartilage preservation, and functional improvement), and adherence to Good Laboratory Practice (GLP) standards. Our team has extensive experience designing preclinical OA studies that align with regulatory expectations, facilitating smooth transitions to clinical development.

Q: What technical aspects are critical for successful preclinical Osteoarthritis research?

A: Technical excellence in OA research hinges on the use of relevant animal models, precise surgical techniques, advanced imaging (such as micro-CT and MRI), and quantitative histopathology. Biomarker analysis and gait assessment are also important for evaluating disease progression and therapeutic efficacy. Our company utilizes state-of-the-art facilities and technologies to deliver high-quality, reproducible data, and our scientific staff are experts in OA-specific methodologies.

Q: How do timeline and cost considerations impact preclinical Osteoarthritis drug development?

A: OA studies typically require longer timelines due to the chronic and progressive nature of the disease, with preclinical efficacy studies often spanning several months. This extended duration, coupled with the need for specialized models and endpoints, can increase costs. Our company mitigates these challenges by offering efficient study designs, in-house expertise, and integrated services that streamline workflows—ultimately reducing both time and expense while maintaining scientific rigor.

Q: What are the critical success factors in preclinical Osteoarthritis drug development?

A: Key success factors include the selection of appropriate disease models, use of clinically relevant endpoints, rigorous study design, and early engagement with regulatory authorities. Collaboration with experienced preclinical partners is also essential for navigating technical and regulatory complexities. Our company’s comprehensive approach—encompassing model selection, study execution, data analysis, and regulatory support—ensures that our clients’ OA drug candidates are positioned for success in subsequent clinical development.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © 2025 Protheragen. All rights reserved.